Global pharma major Lupin has launched a strategic partnership programme aimed at expanding the reach of PrecisionSphere – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi.

The initiative follows the US Food and Drug Administration (US FDA) approval of the first product developed using the platform, marking its readiness for commercial use.

Its partnership programme is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations.

“With the validation of PrecisionSphere’s capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations,” said Dr. Fabrice Egros, President – Corporate Development, Lupin.

“Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to patients at an accelerated pace,” he added.

According to Lupin, PrecisionSphere addresses key compliance issues that lead pharmaceutical companies to lose millions in revenue and experience failed treatment results.  Unlike conventional LAI technologies that yield variable particle sizes, the platform enables the manufacture of medicines with consistent particle size, shape, and biological properties, leading to improved injectability and optimized drug levels—the release of consistent drug concentrations throughout the treatment, ranging from weeks to months.

Dr. Shahin Fesharaki, Chief Scientific Officer, Lupin, said, “PrecisionSphere reflects our commitment to innovation and leverages our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower entry barriers for developing LAIs. This allows partners to efficiently bring advanced LAIs to market across various therapeutic areas and potentially extend the patent life of their products.”

Headquartered in Mumbai, India, Lupin is a leading global pharmaceutical company engaged in the development and manufacture of branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs).